Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group

References

• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164–1174.
   PubMed Web of Science ®Google Scholar
• Tam CS, O’Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112: 975–980.
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370: 1101–1110.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet 2015; 385: 1873–1883.
   PubMed Web of Science ®Google Scholar
• Wildiers H. Mastering chemotherapy dose reduction in elderly cancer patients. Eur J Cancer 2007; 43: 2235–2241.
   PubMed Web of Science ®Google Scholar
• Lichtman SM, Wildiers H, Launay-Vacher V, et al. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007; 43: 14–34.
   PubMed Web of Science ®Google Scholar
• Brunello A, Loaldi E, Balducci L. Dose adjustment and supportive care before and during treatment. Cancer Treat Rev 2009; 35: 493–498.
   PubMed Web of Science ®Google Scholar
• Balducci L. Supportive care in elderly cancer patients. Curr Opin Oncol 2009; 21: 310–317.
   PubMed Web of Science ®Google Scholar
• Shayne M, Balducci L. Hematopoietic growth factors in older cancer patients. Cancer Treat Res 2011; 157: 383–402.
   PubMedGoogle Scholar
• Goodnough LT, Schrier SL. Evaluation and management of anemia in the elderly. Am J Hematol 2014; 89: 88–96.
   PubMed Web of Science ®Google Scholar
• Balducci L. Cancer-related anemia: special considerations in the elderly. Oncology (Williston Park) 2007; 21: 81–86, 90; discussion 90, 100,104.
   PubMed Web of Science ®Google Scholar
• Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology Consensus on Geriatric Assessment in Older Patients With Cancer. J Clin Oncol 2014; 32: 2595–2603.
   PubMed Web of Science ®Google Scholar
• Hamaker ME, Prins MC, Stauder R. The relevance of a geriatric assessment for elderly patients with a haematological malignancy – a systematic review. Leuk Res 2014; 38: 275–283.
   PubMed Web of Science ®Google Scholar
• Parmelee PA, Thuras PD, Katz IR, et al. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc 1995; 43: 130–137.
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41.
   PubMed Web of Science ®Google Scholar
• Salvi F, Miller MD, Grilli A, et al. A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc 2008; 56: 1926–1931.
   PubMed Web of Science ®Google Scholar
• Podsiadlo D, Richardson S. The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991; 39: 142–148.
   PubMed Web of Science ®Google Scholar
• Kalbe E, Kessler J, Calabrese P, et al. DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. Int J Geriatr Psychiatry 2004; 19: 136–143.
   PubMed Web of Science ®Google Scholar
• Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 179–186.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997.
   PubMed Web of Science ®Google Scholar
• Bezares RF, Murro HH, Celebrin L, et al. Fludarabine (F) administered on a three (F3a) alternate day-basis in selected CLL patients. Leuk Lymphoma 2001; 42: 53.
   Google Scholar
• Denson AC, Mahipal A. Participation of the elderly population in clinical trials: barriers and solutions. Cancer Control 2014; 21: 209–214.
   PubMed Web of Science ®Google Scholar
• Basche M, Baron AE, Eckhardt SG, et al. Barriers to enrollment of elderly adults in early-phase cancer clinical trials. J Oncol Pract 2008; 4: 162–168.
   PubMedGoogle Scholar
• Javid SH, Unger JM, Gralow JR, et al. A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316). Oncologist 2012; 17: 1180–1190.
   PubMed Web of Science ®Google Scholar
• Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 1255–1260.
   PubMed Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009; 373: 1532–1542.
   PubMed Web of Science ®Google Scholar
• Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2012; 12: CD003407.
   PubMed Web of Science ®Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370: 997–1007.
   PubMed Web of Science ®Google Scholar
• Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998; 16: 1582–1587.
   PubMed Web of Science ®Google Scholar
• Martell RE, Peterson BL, Cohen HJ, et al. Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study. Cancer Chemother Pharmacol 2002; 50: 37–45.
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 1756–1765.
   PubMed Web of Science ®Google Scholar
• Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865–2874.
   PubMed Web of Science ®Google Scholar
• Osterborg A, Brandberg Y, Molostova V, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol 2002; 20: 2486–2494.
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002; 94: 1211–1220.
   PubMed Web of Science ®Google Scholar
• Canon JL, Vansteenkiste J, Bodoky G, et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006; 98: 273–284.
   PubMed Web of Science ®Google Scholar
• Smolej L, Brychtova Y, Doubek M, et al. Low-dose FCR is a safe and effective treatment option for elderly/comorbid patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Updated results of Project Q-Lite by Czech CLL Study Group. Blood 2014; 124: 4670.
   Web of Science ®Google Scholar